Susquehanna Fundamental Investments’s Intellia Therapeutics NTLA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$637K	Buy	+37,663	New	+$527K	0.01%	524
2026 Q1	–	Sell	-69,226	Closed	-$622K	–	628
2025 Q4	$622K	Sell	69,226 -86,978	-56%	-$1.2M	0.02%	405
2025 Q3	$2.7M	Hold	156,204	–	–	0.11%	204
2025 Q2	$1.47M	Hold	156,204	–	–	0.04%	390
2025 Q1	$1.11M	Buy	+156,204	New	+$1.58M	0.02%	666
2021 Q4	–	Sell	-12,438	Closed	-$1.67M	–	1668
2021 Q3	$1.67M	Sell	12,438 -31,617	-72%	-$4.79M	0.03%	657
2021 Q2	$7.13M	Hold	44,055	–	–	0.13%	215
2021 Q1	$3.54M	Hold	44,055	–	–	0.06%	447
2020 Q4	$2.4M	Hold	44,055	–	–	0.04%	572
2020 Q3	$876K	Buy	+44,055	New	+$919K	0.03%	686

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Susquehanna Fundamental Investments's NTLA Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 37,663 shares worth $637K. The stake represents 0.01% of the portfolio and ranks #524 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in NTLA as recently as Q4 2025.

Susquehanna Fundamental Investments first reported a position in NTLA in Q3 2020 and has held it in 10 quarters since. The position peaked at $7.13M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Susquehanna Fundamental Investments held 37,663 shares of Intellia Therapeutics worth $637K as of Q2 2026.
Intellia Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2026.
Intellia Therapeutics made up 0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #524 holding.
Susquehanna Fundamental Investments first reported a position in Intellia Therapeutics in Q3 2020 and has held it in 10 quarters since.
Susquehanna Fundamental Investments's Intellia Therapeutics position peaked at $7.13M in Q2 2021.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.